Thursday, October 13, 2022 4:58:42 AM
Management is inept
Once I spoke to the CFO and he clearly does not know anything about being a CFO of a public company.
The CEO on the other hand does not understand the importance of letting investors know about his company. He keeps raising capital from investors at such bad terms the only people that will ever make money are his bankers and the people that continue to short the stock.
Some people have no right to raise capital because although they are not a scam, there is no chance of their stock increasing because management is inept or they don't understand the markets.
Once I spoke to the CFO and he clearly does not know anything about being a CFO of a public company.
The CEO on the other hand does not understand the importance of letting investors know about his company. He keeps raising capital from investors at such bad terms the only people that will ever make money are his bankers and the people that continue to short the stock.
Some people have no right to raise capital because although they are not a scam, there is no chance of their stock increasing because management is inept or they don't understand the markets.
Recent OTLC News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics • GlobeNewswire Inc. • 06/01/2026 11:30:00 AM
- Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026 • GlobeNewswire Inc. • 05/28/2026 12:30:00 PM
- Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress • GlobeNewswire Inc. • 05/15/2026 01:00:00 PM
- NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 09:16:22 PM
- Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform • GlobeNewswire Inc. • 05/14/2026 12:30:00 PM
- Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus • GlobeNewswire Inc. • 05/13/2026 02:00:00 PM
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research • InvestorsHub NewsWire • 05/13/2026 01:00:00 PM
- CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies • GlobeNewswire Inc. • 05/12/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease • GlobeNewswire Inc. • 05/06/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:21:45 PM
- Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts • GlobeNewswire Inc. • 04/30/2026 12:30:00 PM
- NetworkNews Audio Announces Audio Press Release (APR) Discussing Advancing Oncology Therapeutics, Strategic Positioning within High-Value Development Pathways • GlobeNewswire Inc. • 04/24/2026 12:30:00 PM
- Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy • GlobeNewswire Inc. • 04/24/2026 12:00:00 PM
- Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution • GlobeNewswire Inc. • 04/21/2026 12:30:00 PM
- When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech • InvestorsHub NewsWire • 04/20/2026 01:00:00 PM
- When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 01:00:28 PM
- Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress • GlobeNewswire Inc. • 04/16/2026 12:30:00 PM
